

Fecha del CVA	20/04/2023
---------------	------------

## Parte A. DATOS PERSONALES

Nombre *	María		
Apellidos *	Buti Ferret		
Sexo *		Fecha de Nacimiento *	
DNI/NIE/Pasaporte *		Teléfono *	
URL Web			
Dirección Email	mariaasuncion.butí@vallhebron.cat		
Identificador científico	Open Researcher and Contributor ID (ORCID) *	0000-0002-0732-3078	
	Researcher ID		
	Scopus Author ID	7007153523	

\* Obligatorio

### A.1. Situación profesional actual

Puesto	Jefe Clínico de Medicina interna		
Fecha inicio	1995		
Organismo / Institución	Hospital Universitario Vall d'Hebron		
Departamento / Centro	Medicina Interna 2/ Hepatología / Hospital General/ Vall d'Hebrón Institut de Recerca (VHIR)		
País		Teléfono	
Palabras clave	Medicina clínica		

### A.3. Formación académica

Grado/Master/Tesis	Universidad / País	Año
Programa Oficial de Doctorado en Medicina y Cirugía	Universitat Autònoma de Barcelona / España	1985
Licenciado en Medicina y Cirugía	Universitat de Barcelona / España	1979

### A.4. Indicadores generales de calidad de la producción científica

A lo largo de mi carrera, entre 1983 y 2022, he participado en **547 publicaciones** científicas (artículos científicos, revisiones bibliográficas, cartas al editor...) con **46759 citas**, que dan lugar a un **índice h = 91**. De estas 180 se han publicado en los últimos 5 años, con **22579 citas**, que dan lugar a un **índice h = 61** (fuente Google Scholar, <https://scholar.google.com/citations?user=sppAhzYAAAAJ&hl=ca&inst=2086209426759054600&oi=ao>). En este currículum se detallan las publicaciones y participaciones en congresos nacionales e internacionales más destacadas de los últimos 5 años.

## Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Mi actividad científica se ha centrado en la investigación de las hepatitis virales, especialmente la hepatitis crónica B, C, Delta y E. Esta actividad se ha desarrollado principalmente participando y dirigiendo estudios clínicos y de laboratorio en el Hospital Vall d'Hebron (Barcelona) y en muchos casos son fruto de colaboraciones nacionales e internacionales, como se puede apreciar en la producción científica y colaboración en proyectos de investigación mostrados en este currículum.

En mi actividad asistencial, destacan la colaboración en la elaboración de diferentes **guías clínicas nacionales e internacionales**. En los **últimos 5 años (desde 2018)** he participado en la elaboración de 2 de ellas:

1. Jose L. Calleja, Juan Macias, Xavier Forns, et al. Guía de tratamiento de la infección por virus de la hepatitis C. Asociación Española para el Estudio del Hígado (AEEH). Gastroenterol Hepatol. 2018;41:597-608.
2. Rodriguez M, Buti M, Esteban R, et al. Documento de consenso de la Asociación Española para el Estudio del Hígado sobre el tratamiento de la infección por el virus de la hepatitis B (2020). Gastroenterol Hepatol. 2020;43:559-87.

También a destacar que desde la fundación del CIBER en el año 2006 hasta la actualidad **pertenezco al grupo CB06/04/0025 del CIBERehd, que desde 2020 dirijo como investigadora principal.**

En cuanto a mi **actividad docente**, desde 1995 soy profesora titular del departamento de medicina de la Universitat Autònoma de Barcelona (UAB) y desde 2011 soy catedrático de universidad de ese departamento.

## Parte C. MÉRITOS MÁS RELEVANTES

### C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores. Si aplica, indique el número de citaciones

- 1 **Artículo científico.** Aggarwal, Abhishek; Odorizzi, Pamela M; Brodbeck, Jens; et al; Balsitis, Scott. 2023. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells. JHEP reports : innovation in hepatology. 5-4, pp.100664. ISSN 2589-5559. WOS (0)
- 2 **Artículo científico.** Riveiro-Barciela, Mar; Barreira-Diaz, Ana; Callejo-Perez, Ana; et al; Buti, Maria. 2023. Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. ELSEVIER SCIENCE INC. 21-3, pp.732-740. ISSN 1542-3565, ISSN 1542-7714. WOS (3)
- 3 **Artículo científico.** Cortesi, Paolo Angelo; Viganò, Raffaella; Conti, Sara; et al; Belli, Luca Saverio. 2023. Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation. TRANSPLANT INTERNATIONAL. FRONTIERS MEDIA SA. 36. ISSN 0934-0874, ISSN 1432-2277. WOS (0)
- 4 **Artículo científico.** Yuen, Man-Fung; Lim, Seng-Gee; Plesniak, Robert; et al; B-Clear Study Grp. 2022. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. NEW ENGLAND JOURNAL OF MEDICINE. MASSACHUSETTS MEDICAL SOC. 387-21, pp.1957-1968. ISSN 0028-4793, ISSN 1533-4406. WOS (10)
- 5 **Artículo científico.** Palom, Adriana; Rando-Segura, Ariadna; Vico, Judit; et al; Buti, Maria. 2022. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP REPORTS. ELSEVIER. 4-10. ISSN 2589-5559. WOS (4)
- 6 **Artículo científico.** Sonneveld, Milan J.; Hansen, Bettina E.; Brouwer, Willem P.; et al; Janssen, Harry L. A.; Buti, Maria. (14/16). 2022. Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study. JOURNAL OF INFECTIOUS DISEASES. OXFORD UNIV PRESS INC. 225-11, pp.1967-1973. ISSN 1537-6613. WOS (3) <https://doi.org/10.1093/jiaa192>
- 7 **Artículo científico.** Cortese, Maria Francesca; Riveiro-Barciela, Mar; Tabernero, David; et al; Rodriguez-Frias, Francisco; Buti, Maria. (18/19). 2022. Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up. Microbiology spectrum. 10-2, pp.e0214921. ISSN 2165-0497. WOS (0) <https://doi.org/10.1128/spectrum.02149-21>

- 8 **Artículo científico.** Riveiro-Barciela, Mar; Barreira-Diaz, Ana; Callejo-Perez, Ana; et al; Buti, Maria; Buti, Maria. (9/9). 2022. Retreatment With Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. ISSN 1542-7714. WOS (0) <https://doi.org/10.1016/j.cgh.2022.03.050>
- 9 **Artículo científico.** Sonneveld, Milan J.; Chiu, Shao-Ming; Park, Jun Yong; et al; CREATE Study Grp. 2022. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. *JOURNAL OF HEPATOLOGY. ELSEVIER*. 76-5, pp.1042-1050. ISSN 0168-8278, ISSN 1600-0641. WOS (13)
- 10 **Artículo científico.** Pacin-Ruiz, Beatriz; Cortese, Maria Francesca; Tabernero, David; et al; Rodriguez-Frias, Francisco; Buti, Maria. (17/18). 2022. Inspecting the Ribozyme Region of Hepatitis Delta Virus Genotype 1: Conservation and Variability. *VIRUSES-BASEL. MDPI*. 14-2. ISSN 1999-4915. WOS (0) <https://doi.org/10.3390/v14020215>
- 11 **Artículo científico.** van Buuren, Nicholas; Ramirez, Ricardo; Turner, Scott; et al; Feierbach, Becket; Buti, Maria. (14/21). 2022. Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection. *JHEP REPORTS. ELSEVIER*. 4-1. ISSN 2589-5559. WOS (1) <https://doi.org/10.1016/j.jhepr.2021.100388>
- 12 **Artículo científico.** Polaris Observatory HCV Collaborators. 2022. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. *The lancet. Gastroenterology & hepatology*. 7-5, pp.396-415. ISSN 2468-1253. WOS (2) [https://doi.org/10.1016/S2468-1253\(21\)00472-6](https://doi.org/10.1016/S2468-1253(21)00472-6)
- 13 **Artículo científico.** Sonneveld, Milan J; Chiu, Shao-Ming; Park, Jun Yong; et al; CREATE study group; Buti, Maria. (22/27). 2022. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. *Journal of hepatology*. 76-5, pp.1042-1050. ISSN 1600-0641. WOS (2) <https://doi.org/10.1016/j.jhep.2022.01.007>
- 14 **Artículo científico.** Nakanishi, Tomoko; Pigazzini, Sara; Degenhardt, Frauke; et al; COVID-19 Host Genetics Initiative; Buti, Maria. (38/49). 2021. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. *JOURNAL OF CLINICAL INVESTIGATION. AMER SOC CLINICAL INVESTIGATION INC*. 131-23. ISSN 0021-9738. WOS (18) <https://doi.org/10.1172/JCI152386>
- 15 **Artículo científico.** Lazarus, Jeffrey, V; Mark, Henry E.; Anstee, Quentin M.; et al; NAFLD Consensus Consortium. 2021. Advancing the global public health agenda for NAFLD: a consensus statement. *NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY. NATURE PORTFOLIO*. 19-1, pp.60-78. ISSN 1759-5045. WOS (17) <https://doi.org/10.1038/s41575-021-00523-4>
- 16 **Artículo científico.** COVID-19 Host Genetics Initiative. 2021. Mapping the human genetic architecture of COVID-19. *NATURE. NATURE PORTFOLIO*. 600-7889, pp.472-+. ISSN 1476-4687. WOS (117) <https://doi.org/10.1038/s41586-021-03767-x>
- 17 **Artículo científico.** Palom, Adriana; Sopena, Sara; Riveiro-Barciela, Mar; et al; Buti, Maria; Buti, Maria (AC). (17/17). 2021. One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. *ALIMENTARY PHARMACOLOGY & THERAPEUTICS. WILEY*. 54-4, pp.462-469. ISSN 0269-2813. WOS (7) <https://doi.org/10.1111/apt.16485>
- 18 **Artículo científico.** Buti, Maria (AC); Stepanova, Maria; Palom, Adriana; Riveiro-Barciela, Mar; Nader, Fatema; Roade, Luisa; Esteban, Rafael; Younossi, Zobair. (1/8). 2021. Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. *JHEP REPORTS. ELSEVIER*. 3-3. ISSN 2589-5559. WOS (0) <https://doi.org/10.1016/j.jhepr.2021.100280>

- 19 Artículo científico.** Garcia-Garcia, Selene; Cortese, Maria Francesca; Rodriguez-Algarra, Francisco; Tabernero, David; Rando-Segura, Ariadna; Quer, Josep; Buti, Maria; Rodriguez-Frias, Francisco. (7/8). 2021. Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS. TAYLOR & FRANCIS AS. 21-4, pp.381-396. ISSN 1744-8352. WOS (5) <https://doi.org/10.1080/14737159.2021.1913055>
- 20 Artículo científico.** Llaneras, Jordi; Riveiro-Barciela, Mar; Rando-Segura, Ariadna; et al; Buti, Maria; Buti, Maria (AC). (9/9). 2021. Etiologies and Features of Acute Viral Hepatitis in Spain. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. ELSEVIER SCIENCE INC. 19-5, pp.1030-1037. ISSN 1542-7714. WOS (2) <https://doi.org/10.1016/j.cgh.2020.07.006>
- 21 Artículo científico.** Brunetto, Maurizia R.; Carey, Ivana; Maasoumy, Benjamin; et al; Buti, Maria; Buti, Maria. (20/20). 2021. Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. WILEY. 53-6, pp.733-744. ISSN 1365-2036. WOS (4) <https://doi.org/10.1111/apt.16258>
- 22 Artículo científico.** Papatheodoridis, George, V; Dalekos, George N.; Idilman, Ramazan; et al; Lampertico, Pietro; Buti, Maria. (6/24). 2020. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. JOURNAL OF HEPATOLOGY. ELSEVIER. 73-5, pp.1037-1045. ISSN 0168-8278. WOS (35) <https://doi.org/10.1016/j.jhep.2020.06.011>
- 23 Artículo científico.** Ellinghaus, David; Degenhardt, Frauke; Bujanda, Luis; et al; Severe Covid-19 GWAS Grp; Buti, Maria. (4/147). 2020. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. NEW ENGLAND JOURNAL OF MEDICINE. MASSACHUSETTS MEDICAL SOC. 383-16, pp.1522-1534. ISSN 1533-4406. WOS (820) <https://doi.org/10.1056/NEJMoa2020283>
- 24 Artículo científico.** Zoulim, Fabien; Lenz, Oliver; Vandenbossche, Joris J.; et al; Yogaratnam, Jeysen Z.; Buti, Maria. (9/16). 2020. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. GASTROENTEROLOGY. W B SAUNDERS CO-ELSEVIER INC. 159-2, pp.521+. ISSN 0016-5085. WOS (30) <https://doi.org/10.1053/j.gastro.2020.04.036>
- 25 Artículo científico.** Riveiro-Barciela, Mar; Barreira-Diaz, Ana; Vidal-Gonzalez, Judit; et al; Buti, Maria; Buti, Maria (AC). (11/11). 2020. Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. LIVER INTERNATIONAL. WILEY. 40-8, pp.1906-1916. ISSN 1478-3223. WOS (15) <https://doi.org/10.1111/liv.14489>
- 26 Artículo científico.** Lampertico, Pietro; Buti, Maria; Fung, Scott; et al; Chan, Henry L. Y.(2/24). 2020. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. LANCET GASTROENTEROLOGY & HEPATOLOGY. ELSEVIER INC. 5-5, pp.441-453. ISSN 2468-1253. WOS (44) [https://doi.org/10.1016/S2468-1253\(19\)30421-2](https://doi.org/10.1016/S2468-1253(19)30421-2)
- 27 Artículo científico.** Sonneveld, Milan J; Hansen, Bettina E; Brouwer, Willem P; et al; SONIC-B Study group; Buti, Maria. (14/17). 2020. hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study. The Journal of infectious diseases. ISSN 1537-6613. WOS (3) <https://doi.org/10.1093/jiaa192>
- 28 Artículo científico.** Cornberg, Markus; Lok, Anna Suk-Fong; Terrault, Norah A.; Zoulim, Fabien; 2019 EASL-AASLD HBV Treatment Endp. 2020. Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B-Report From the 2019 EASL-AASLD HBV Treatment Endpoints Conference. HEPATOLOGY. WILEY. 71-3, pp.1070-1092. ISSN 0270-9139. WOS (58) <https://doi.org/10.1002/hep.31030>
- 29 Artículo científico.** Palom A; Rodríguez-Tajes S; Navascués CA; et al; Buti M; Buti M. (9/9). 2020. Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. Alimentary pharmacology & therapeutics. 51, pp.158-166. ISSN 0269-2813. <https://doi.org/10.1111/apt.15521>

- 30 Artículo científico.** Llaneras J; Riveiro-Barciela M; Lens S; et al; Buti M; Buti M. (33/33). 2019. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. *Journal of hepatology*. 71, pp.666-672. ISSN 0168-8278. WOS (1) <https://doi.org/10.1016/j.jhep.2019.06.002>
- 31 Artículo científico.** Riveiro-Barciela M; Gironella M; Senín A; et al; Martínez-Valle F; Buti M. (8/9). 2019. Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory?. *Hepatology (Baltimore, Md.)*. 69, pp.2701-2703. ISSN 0270-9139. <https://doi.org/10.1002/hep.30464>
- 32 Artículo científico.** Zeuzem S; Bourgeois S; Greenbloom S; et al; OMEGA-1 study team.; Buti M. (4/22). 2019. JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. *Hepatology (Baltimore, Md.)*. 69, pp.2349-2363. ISSN 0270-9139. WOS (2) <https://doi.org/10.1002/hep.30527>
- 33 Artículo científico.** Karimzadeh H; Kiraithe MM; Oberhardt V; et al; Neumann-Haefelin C; Buti M. (15/29). 2019. Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8<sup>+</sup> T Cells and Evolve at the Population Level. *Gastroenterology*. 156, pp.1820-1833. ISSN 0016-5085. WOS (3) <https://doi.org/10.1053/j.gastro.2019.02.003>
- 34 Artículo científico.** Buti M; Wong DK; Gane E; et al; Marcellin P. (1/14). 2019. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. *The lancet. Gastroenterology & hepatology*. 4, pp.296-304. [https://doi.org/10.1016/S2468-1253\(19\)30015-9](https://doi.org/10.1016/S2468-1253(19)30015-9)
- 35 Artículo científico.** Riveiro-Barciela M; Muñoz-Couselo E; Fernandez-Sojo J; Diaz-Mejia N; Parra-López R; Buti M. (6/6). 2019. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?. *Journal of hepatology*. 70, pp.564-566. ISSN 0168-8278. WOS (3) <https://doi.org/10.1016/j.jhep.2018.10.020>
- 36 Artículo científico.** Yeo YH; Ho HJ; Yang HI; et al; Nguyen MH; Buti M. (10/39). 2019. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. *Gastroenterology*. 156, pp.635-646.e9. ISSN 0016-5085. WOS (10) <https://doi.org/10.1053/j.gastro.2018.10.027>
- 37 Artículo científico.** Esteban R; Pineda JA; Calleja JL; et al; Buti M; Buti M. (22/22). 2018. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. *Gastroenterology*. 155, pp.1120-1127.e4. ISSN 0016-5085. WOS (4) <https://doi.org/10.1053/j.gastro.2018.06.042>
- 38 Artículo científico.** Karimzadeh H; Kiraithe MM; Kosinska AD; et al; Roggendorf M; Buti M. (19/33). 2018. Amino Acid Substitutions within HLA-B\*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8<sup>+</sup> T Cells. *Journal of virology*. 92. ISSN 0022-538X. WOS (3) <https://doi.org/10.1128/JVI.01891-17>
- 39 Artículo científico.** Wranke A; Pinheiro Borzacov LM; Parana R; et al; Hepatitis Delta International Network.; Buti M. (14/26). 2018. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). *Liver international : official journal of the International Association for the Study of the Liver*. 38, pp.842-850. ISSN 1478-3223. WOS (10) <https://doi.org/10.1111/liv.13604>
- 40 Artículo científico.** Poordad F; Pol S; Asatryan A; et al; Mensa FJ; Buti M. (4/20). 2018. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. *Hepatology (Baltimore, Md.)*. 67, pp.1253-1260. ISSN 0270-9139. WOS (25) <https://doi.org/10.1002/hep.29671>
- 41 Artículo científico.** 2018. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol*. 3-6, pp.383-403.
- 42 Artículo científico.** Wong D; Littlejohn M; Yuen L; et al; Revill PA; Buti M. (12/17). 2018. HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients. *Alimentary pharmacology & therapeutics*. 47, pp.114-122. ISSN 0269-2813. <https://doi.org/10.1111/apt.14362>

- 43 Artículo científico.** Sopena, S; Godoy, C; Tabernero, D; et al; Rodriguez-Frias, F; Buti, M. (9/10). 2018. Quantitative characterization of hepatitis delta virus genome edition by next-generation sequencing. *VIRUS RESEARCH*. 243, pp.52-59. ISSN 0168-1702.
- 44 Revisión bibliográfica.** Riveiro-Barciela, Mar; Pericas, Juan M; Buti, Maria. (1/3). 2022. How to interpret viral markers in the management of chronic hepatitis B infection. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 28-3, pp.355-361. ISSN 1469-0691. WOS (0) <https://doi.org/10.1016/j.cmi.2021.10.020>
- 45 Revisión bibliográfica.** Karlsen, Tom H.; Sheron, Nick; Zelber-Sagi, Shira; et al; Manns, Michael P.; Buti, Maria. (54/57). 2021. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. *LANCET*. 399-10319, pp.61-116. ISSN 1474-547X. WOS (19) [https://doi.org/10.1016/S0140-6736\(21\)01701-3](https://doi.org/10.1016/S0140-6736(21)01701-3)
- 46 Revisión bibliográfica.** Buti, Maria (AC); Riveiro-Barciela, Mar; Rodriguez-Frias, Francisco; Tabernero, David; Esteban, Rafael. (1/5). 2020. Role of Biomarkers in Guiding Cure of Viral Hepatitis B. *SEMINARS IN LIVER DISEASE*. 40-1, pp.49-60. ISSN 0272-8087. WOS (5) <https://doi.org/10.1055/s-0039-3401031>
- 47 Revisión bibliográfica.** Lazarus JV; Picchio C; Dillon JF; Rockstroh JK; Weis N; Buti M. (6/6). 2019. Too many people with viral hepatitis are diagnosed late - with dire consequences. *Nature reviews. Gastroenterology & hepatology*. 16, pp.451-452. ISSN 1759-5045. WOS (1) <https://doi.org/10.1038/s41575-019-0177-z>
- 48 Revisión bibliográfica.** Yurdaydin C; Abbas Z; Buti M; et al; Hepatitis Delta International Network (HDIN).(3/20). 2019. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. *Journal of hepatology*. 70, pp.1008-1015. ISSN 0168-8278. WOS (8) <https://doi.org/10.1016/j.jhep.2018.12.022>
- 49 Revisión bibliográfica.** Tabernero D; Cortese MF; Buti M; Rodriguez-Frias F. (3/4). 2018. HDV evolution-will viral resistance be an issue in HDV infection?. *Current opinion in virology*. 32, pp.100-107. ISSN 1879-6257. <https://doi.org/10.1016/j.coviro.2018.10.003>
- 50 Carta.** Tabernero, David; Cortese, Maria Francesca; Rando-Segura, Ariadna; Buti, Maria; Rodriguez-Frias, Francisco. (4/5). 2021. Letter to the editor: Standardization of HBV-RNA assay for the different phases of chronic hepatitis B is essential. *HEPATOLOGY*. 75-2, pp.501-502. ISSN 0270-9139. WOS (0) <https://doi.org/10.1002/hep.32227>
- 51 Editorial.** Palom, Adriana; Riveiro-Barciela, Mar; Buti, Maria. (3/3). 2020. Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Authors' reply. *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*. 51-1, pp.174-175. ISSN 1365-2036. WOS (1) <https://doi.org/10.1111/apt.15558>
- 52** Riveiro-Barciela, Mar; Palom, Adriana; Buti, Maria. 2022. Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer?. *ALIMENTARY PHARMACOLOGY & THERAPEUTICS*. 56-5, pp.912-913. ISSN 0269-2813, ISSN 1365-2036. WOS (1)
- 53** Buti, Maria. 2022. HEPATITIS D VIRUS: MORE ATTENTION NEEDED. *NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY*. 19-9, pp.556-556. ISSN 1759-5045, ISSN 1759-5053. WOS (0)
- 54** Buti, Maria; Stepanova, Maria; Palom, Adriana; Riveiro-Barciela, Mar; Nader, Fatema; Roade, Luisa; Esteban, Rafael; Younossi, Zobair. 2022. Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B (vol 3, 100280, 2021). *JHEP REPORTS*. 4-9. ISSN 2589-5559. WOS (0)
- 55** Degenhardt, Frauke; Ellinghaus, David; Juzenas, Simonas; et al; Franke, Andre. 2022. Detailed stratified GWAS analysis for severe COVID-19 in four European populations. *Human molecular genetics*. 31-23, pp.3945-3966. ISSN 1460-2083. WOS (7)

## C.2. Congresos

- 1** HEPATITIS INMUNOMEDIADA COMO NUEVA ENTIDAD INDEPENDIENTE DE LA HEPATITIS AUTOINMUNE: DIFERENCIAS CLÍNICAS Y PRONÓSTICAS. 44º Congreso anual de la AEEH. Asociación Española para el Estudio del Hígado. 2019.

- 2 INMUNOGENICIDAD DE LA VACUNA CONTRA EL VIRUS DE LA HEPATITIS B EN PACIENTES INMUNOSUPRIMIDOS ANTIHBC POSITIVO CON NIVELES BAJOS DE ANTIHBS: RESULTADOS PRELIMINARES DEL ESTUDIO HEPBARE. 44º Congreso anual de la AEEH. Asociación Española para el Estudio del Hígado. 2019.
- 3 Antiviral Activity of a New siRNA Targeting a Hyper-Conserved Region in Hepatitis B X Gene Transcripts: Preliminary Data. The Liver Meeting. American association for the study of the liver. 2018.
- 4 Wagner, Josef; Yuen, Lilly; Littlejohn, Margaret; et al; Revill, Peter. Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease.
- 5 Palom, Adriana; Rando-Segura, Ariadna; Rodriguez-Frias, Francisco; Barreira, Ana; Llaneras, Jordi; Riveiro Barciela, Mar; Esteban, Rafael; Buti, Maria. Anti-HDV reflex testing increases the number of hepatitis D cases diagnosed in both academic and community centers. International Liver Congress.
- 6 Buti, Maria; Wedemeyer, Heiner; Aleman, Soo; et al; Lampertico, Pietro. BULEVIRTIDE IMPROVES HEALTH RELATED QUALITY LIFE MEASURED BY EQ-5D VAS IN PATIENTS WITH CHRONIC HEPATITIS DELTA: AN EXPLORATORY ANALYSIS OF A PHASE 3 TRIAL AT 48 WEEKS.
- 7 Buti, Maria; Calleja Panero, Jose Luis; Rodriguez Sagrado, Miguel Angel; Cantero, Helena; de las Heras, Ana; Dominguez-Hernandez, Raquel; Angel Casado, Miguel. Bulevirtide avoids future clinical events and related costs compared to pegylated-interferon alpha in chronic hepatitis D in Spain.
- 8 Arici, Sena; Palom, Adriana; Gumussoy, Mesut; et al; Yurdaydin, Cihan. Chronic hepatitis delta with normal ALT and hepatitis D viremia.
- 9 Pacin, Beatriz; Francesca Cortese, Maria; Gregori, Josep; et al; Buti, Maria. Conservation, variability and evolution of Hepatitis Delta virus in antigen coding region. International Liver Congress.
- 10 Roade, Luisa; Sopena Santistevé, Sara; Pfefferkorn, Maria; et al; Buti, Maria. HBsAg protein composition differs across stages of hepatitis B and hepatitis Delta: a validation cohort study.
- 11 Buti, Maria; Stepanova, Maria; Palom, Adriana; Riveriro, Mar; Esteban-Mur, Rafael; Younossi, Zobair M.. HEPATITIS DELTA INFECTION IS ASSOCIATED WITH IMPAIRMENT OF PATIENT REPORTED OUTCOMES (PROs). Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. Amer Assoc Study Liver Dis.
- 12 Sopena Santistevé, Sara; Godoy, Cristina; Francesca Cortese, Maria; et al; Buti, Maria. HIGHER LEVELS OF LHBS HAVE BEEN FOUND IN BOTH CHB AND CHD PATIENTS WITH LOWER HBsAg VALUES. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. Amer Assoc Study Liver Dis.
- 13 Pacin Ruiz, Beatriz; Francesca Cortese, Maria; Sopena Santistevé, Sara; et al; Buti, Maria. Hepatitis Delta virus quasispecies conservation and variability in ribozyme region.
- 14 Bourgeois, Stefan; Lim, Young-Suk; Gane, Edward J.; et al; Yuen, Man-Fung. IMC-I109V, a novel T cell receptor (TCR) bispecific (ENVxCD3) designed to eliminate HBV-infected hepatocytes in chronic HBV patients: initial data from a first-in-human study.
- 15 Riveiro Barciela, Mar; Barreira, Ana; Callejo-Perez, Ana; et al; Buti, Maria. Immunological Background Pinpoints Patients at High Risk of Immune-related Hepatitis Recurrence during Check-points Inhibitors Rechallenge. International Liver Congress.
- 16 Etzion, Ohad; Buti, Maria; Yardeni, David; et al; D-LIVR Investigators. LIMITED UTILITY OF NONINVASIVE TESTS FOR PREDICTION OF BIOPSY-PROVEN CIRRHOSIS IN CHRONIC HEPATITIS D INFECTED PATIENTS- INSIGHTS FROM THE D-LIVR TRIAL.
- 17 Palom, Adriana; Rodriguez-Tajes, Sergio; Navascues, Carmen A.; et al; Buti, Maria. LONG-TERM CLINICAL OUTCOMES IN A MULTICENTER SPANISH COHORT OF PATIENTS WITH CHRONIC HEPATITIS DELTA.. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. Amer Assoc Study Liver Dis.

- 18 Buti, Maria; Kaushik, Ankita; Ascanio, Mertixell; Darba, Josep; Kachru, Nandita. Patients with CHD coinfection have greater comorbidities, higher healthcare resource use and costs than CHB mono-infection—results from a Spanish national hospital database.
- 19 Buti, Maria; Kaushik, Ankita; Ascanio, Mertixell; Darba, Josep; Kachru, Nandita. Rising clinical and economic burden among hepatitis D patients who attended Spanish hospitals. International Liver Congress.
- 20 Cortese, Maria Francesca; Casillas, Rosario; Garcia-Pras, Ester; et al; Rodriguez-Frias, Francisco. Silencing HBV expression using LNA gapmers: preliminary data of a new promising strategy.
- 21 Pacin, Beatriz; Camps, Gracian; Tabernero, David; et al; Rodriguez Frias, Francisco. Study of the effect of the hepatitis D virus on the hepatitis B virus quasispecies in mice models by a next-generation sequencing approach.
- 22 Wedemeyer, Heiner; Aleman, Soo; Chulanov, Vladimir; et al; Buti, Maria. TREATMENT WITH BULEVIRTIDE IMPROVES PATIENT REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS DELTA (CHD): AN INTERIM EXPLORATORY ANALYSIS AT WEEK 24.
- 23 Buti, Maria; Wedemeyer, Heiner; Aleman, Soo; et al; Lampertico, Pietro. Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks. International Liver Congress.
- 24 Oberhardt, Valerie; Karimzadeh, Hadi; Kiraithe, Muthamia M.; et al; Neumann-Haefelin, Christoph. Viral escape contributes to the failure of hepatitis D virus-specific CD8+T-cells and drives evolution of HDV. International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL). European Assoc Study Liver.
- 25 Dominguez-Hernandez, Raquel; Palom, Adriana; Rando-Segura, Ariadna; Rodriguez-Frias, Francisco; Barciela, Mar Riveiro; Casado, Miguel Angel; Esteban-Mur, Rafael; Buti, Maria. WHAT IS THE ADDITIONAL COST OF EACH ANTI HDV POSITIVE CASE DETECTED THROUGH REFLEX TESTING.

### C.3. Proyectos y Contratos

- 1 **Proyecto.** IP-cure-B, Immune profiling to guide host-directed interventions to cure HBV infections. Comisión Europea. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/01/2020-31/12/2024. 14.943.030,5 €. Investigador Principal en la Fundación Vall d'Hebron Institut de Recerca.
- 2 **Proyecto.** PI20/01692, Impacto de los haplotipos del HLA y fluctuaciones de la viremia del virus Delta en el desarrollo de eventos clínicos y calidad de vida de los pacientes con hepatitis crónica Delta. Instituto de Salud Carlos III. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/01/2021-31/12/2023. 117.370 €. Investigador principal.
- 3 **Proyecto.** GLD21/00139, D-Mongolia: screening and linkage-to-care for Hepatitis D in Mongolian nationals living in Spain. Gilead Sciences, S.L.. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/11/2021-31/05/2023. 48.763 €. Investigador principal.
- 4 **Proyecto.** GLD19/00080, Simplification of screening and treatment of hepatitis C in immigrant population in Barcelona. Gilead Sciences, S.L.. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/01/2020-31/12/2021. 49.494,28 €. Miembro de equipo.
- 5 **Proyecto.** GLD18-0062, Pilot hepatitis C micro-elimination strategy in Pakistani immigrants in Catalonia through the implementation of a community intervention. Gilead Sciences, S.L.. (FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL). 01/01/2019-31/12/2020. 30.000 €. Miembro de equipo.
- 6 **Proyecto.** GLD17/00276, Diagnostic strategy for the referral of patients with active HCV infection from primary care. Gilead Sciences, S.L.. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/01/2018-31/12/2019. 48.599,66 €. Miembro de equipo.